Ph.D., Site Head and Vice President Antibody R&D, Compugen USA Inc.
Dr. Hunter is the Vice President of Antibody Research and Development at Compugen, overseeing the discovery and development of antibody therapeutics against Compugen-discovered targets. Prior to joining Compugen, Dr. Hunter served as a Senior Director at XOMA, managing strategic and functional activities related to for development of the preclinical antibody pipeline. He began his industry career at Millennium Pharmaceuticals, where he worked on target discovery and translational medicine aspects of Millennium’s internal and partnered small molecule drug programs.
Presentation Title and Company Description
Immunotherapy Showcase: Targeting PVRIG and TIGIT for Cancer Immunotherapy
Compugen is a drug discovery company with a unique, broadly applicable, predictive discovery infrastructure. We are advancing a therapeutic pipeline consisting of early-stage immuno-oncology programs aimed at harnessing the immune system to eradicate cancer